SCHEMBL2942591

SCHEMBL2942591

O=[C]CNC(=O)c1ccc(C=CC(=O)O)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 6/20 0.48
ESR2 Q92731 4/20 0.48
PGR P06401 2/20 0.48
HCAR2 Q8TDS4 2/20 0.47
PKM P14618 2/20 0.47
CA12 O43570 1/20 0.47
AKR1B10 O60218 1/20 0.47
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
CA3 P07451 1/20 0.47
TYR P14679 1/20 0.47
AKR1B1 P15121 1/20 0.47
CA4 P22748 1/20 0.47
CA6 P23280 1/20 0.47
DPP4 P27487 1/20 0.47
CA5A P35218 1/20 0.47
CA7 P43166 1/20 0.47
CA9 Q16790 1/20 0.47
CA14 Q9ULX7 1/20 0.47
CA5B Q9Y2D0 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7747191 0.84 ESR1 (0.54) ESR1ESR2PGRHCAR2PKM
SCHEMBL7747194 0.84 ESR1 (0.54) ESR1ESR2PGRHCAR2PKM
SCHEMBL660161 0.79 HPGD (0.60) ESR1ESR2PGRPKMKDM4E
SCHEMBL660160 0.79 HPGD (0.60) ESR1ESR2PGRPKMKDM4E
SCHEMBL1237240 0.78 CA1 (0.55) ESR1ESR2PGRHCAR2PKM
SCHEMBL6644791 0.78 HDAC2 (0.57) ESR1ESR2PGRHCAR2PKM
SCHEMBL1237242 0.78 CA1 (0.55) ESR1ESR2PGRHCAR2PKM
SCHEMBL6644786 0.78 HDAC2 (0.57) ESR1ESR2PGRHCAR2PKM
SCHEMBL6538970 0.78 NR1H4 (0.51) CA12CA1CA2CA9CA14
SCHEMBL6642558 0.78 ALDH1A1 (0.55) ESR1ESR2PGRKDM4ETHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2231147-A2 COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER Novartis AG (CH) 2010-09-29 EP disclosed
WO-2009076170-A2 COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER NOVARTIS AG (CH) 2009-06-18 WO disclosed
EP-2004163-A2 COMBINATIONS COMPRISING MTOR INHIBITORS FOR TREATING CANCER Novartis Pharma AG (CH) 2008-12-24 EP disclosed
WO-2007124252-A2 COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER NOVARTIS AG (CH) 2007-11-01 WO disclosed